ViraferonPeg (peginterferon-α-2b) / Merck (MSD)  >>  Phase 3
Welcome,         Profile    Billing    Logout  

5 Trials

   Remove Filter

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
ViraferonPeg (peginterferon-α-2b) / Merck (MSD)
Merck_COVID-09: Coronavirus puts drug repurposing on the fast track

Recruiting
3
0
China
ViraferonPeg (peginterferon-α-2b) - Merck (MSD)
Merck, Tongji Hospital
 
 
Merck_ViraferonPeg_C: Clinical Study of Interferon alfa-2b in the 2019-nCoV Pneumonia

Recruiting
3
0
US
ViraferonPeg (peginterferon-α-2b) - Merck (MSD)
Merck, Biogen
 
 
2011-001919-31: DALIAH A Danish Study of Low-dose Interferon Alpha Versus Hydroxyurea in the Treatment of Ph-negative Chronic Myeloid Neoplasias - A National Randomized Prospective Study With Focus on Efficacy, Toxicity and Quality of Life DALIAH Dansk Studie af Lav-dosis Interferon Alpha vs Hydroxyurea i Behandlingen af Ph-Negative kroniske myeloproliferative neoplasier “Et Nationalt Randomiseret Prospektivt Kvalitetssikringsstudie med Særlig Fokus på Effekt, Toxicitet og Livskvalitet”

Ongoing
3
200
Europe
Suspension for injection in pre-filled pen, Capsule, hard, Pegasys, PegIntron, Hydrea
Roskilde sygehus, Swedish Orphan, Ellen og Aage Fausbølls Helsefond af 1975, Fonden til lægevidenskabens Fremme, Odense Universitetshospitals forskningspulje, Region Sjællands og Region Syddanmarks fælles forskningspulje
Chronic myeloid neoplasms Essential thrombocythemia Polycythemia vera primary myelofibrosis Kroniske myeloide neoplasier Essential thrombocythemia Polycythemia vera primary myelofibrosis, Chronic myeloid neoplasms Essential thrombocythemia Polycythemia vera primary myelofibrosis Kroniske myeloide neoplasier Essential thrombocythemia Polycythemia vera primary myelofibrosis, Diseases [C] - Blood and lymphatic diseases [C15]
 
 
2007-000279-40: Randomised phase 3B study on comparison of 2 treatment schedules with peginterferon alpha 2b and ribavirin short term versus standard term schedules in patients with chronic hepatitis C, genotype 2 or 3 and early virologic response comparison of efficacy, tolerability, quality of life and costs.

Ongoing
3
80
Europe
Ribavirin, PEGINTRON, PEGINTRON
A.S.L. 2
Patients with chronic hepatitis C with genotype 2 or 3
 
 
NCT02634294: Peg Interferon α-2b for Relapsed Hematological Malignancies After Allo-HSCT

Completed
2/3
30
RoW
Peg interferon alfa-2b, PEG INTRON®
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Hematological Neoplasms, Recurrence
12/21
12/21

Download Options